{"success":true,"data":{"pressRelease":{"id":"169485","rtpr_id":"nACSFl8k4a-20261014","ticker":"JAGX","exchange":"NASDAQ","all_tickers":["JAGX"],"title":"Jaguar Health Provides Update Regarding Special Stock Dividend","author":"ACCESSWIRE","published_at":"2026-10-14T20:15:00.128Z","article_body":"SAN FRANCISCO, CA / ACCESS Newswire (https://www.accessnewswire.com/) /\nOctober 14, 2026 / Jaguar Health, Inc. (https://pr.report/scwz) (NASDAQ:JAGX\n(https://pr.report/scx0)) (\"Jaguar\" or \"the Company\") today provided an update\nin connection with the Company's previously announced (https://pr.report/scx1)\nspecial stock dividend (the \"Special Stock Dividend\"), which is payable on\nOctober 15, 2026, to holders of Jaguar common stock and certain outstanding\nwarrants as of record on October 13, 2026, to announce that The Nasdaq Stock\nMarket LLC (\"Nasdaq\") has indicated that the ex-dividend date for the Special\nStock Dividend is October 16, 2026 (the \"Ex-Dividend Date\"). The Special Stock\nDividend consists of the Company's Series R Convertible Preferred Stock (the\n\"Preferred Stock\").\n\nNasdaq has advised the Company that its shares of common stock will trade with\n\"due bills\" representing an assignment of the right to receive the dividend\nfrom the record date of October 13, 2026 until the Ex-Dividend Date (this\nperiod of time representing the \"Dividend Right Period\").\n\nStockholders who sell their shares of common stock during the Dividend Right\nPeriod will be selling their right to the Special Stock Dividend. Due bills\nobligate a seller of shares of common stock to deliver the Special Stock\nDividend payable on such shares of common stock to the buyer (the \"Dividend\nRight\"). The record date of October 13, 2026, will be used as the date for\nestablishing the due bill tracking of the Dividend Right to the holder of\nshares of common stock.\n\nDue bill obligations are customarily settled between the brokers representing\nthe buyers and the sellers of shares of common stock. The Company has no\nobligation for either the amount of the due bill or the processing of the due\nbill. Buyers and sellers of the Company's shares of common stock should\nconsult their brokers before trading to be sure they understand the effect of\nNasdaq's due bill procedures.\n\n\"Jaguar is issuing the Special Stock Dividend to reward and recognize our\npassionate and supportive stockholders and provide protection against\npotential dilution as we continue evaluation of strategic alternatives,\" said\nLisa Conte, Jaguar's founder, president, and CEO. \"We remain sharply focused\non our ongoing global development program for oral crofelemer as adjunctive\ntherapy to parenteral support for rare intestinal failure diseases, including\nmicrovillus inclusion disease (MVID) and short bowel syndrome with intestinal\nfailure (SBS-IF) for crofelemer powder for oral solution. Jaguar's intestinal\nfailure program is expected to continue to provide clinical milestones,\nincluding a planned New Drug Application (NDA) filing for crofelemer for MVID\nin mid-2027.\"\n\nFor additional information about the Special Stock Dividend and terms of the\nPreferred Stock and associated risk factors, please refer to the Form 8-K the\nCompany filed with the U.S. Securities and Exchange Commission on October 5,\n2026, which can be viewed on the Company's website by clicking here\n(https://pr.report/scx2).\n\nAbout Crofelemer\n\nCrofelemer is a novel, oral plant-based prescription medicine purified from\nthe red bark sap, also referred to as \"dragon's blood,\" of the Croton lechleri\ntree in the Amazon Rainforest. Napo Pharmaceuticals has established a\nsustainable harvesting program, under fair trade practices, for crofelemer to\nensure a high degree of quality, ecological integrity, and support for\nindigenous communities.\n\nAbout the Jaguar Health Family of Companies\n\nJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company\nfocused on developing novel proprietary prescription medicines sustainably\nderived from plants from rainforest areas for people and animals with\ngastrointestinal distress. Jaguar family companies Napo Pharmaceuticals, Inc.\n(Napo) and Napo Therapeutics S.p.A. focus on the development and\ncommercialization of novel crofelemer powder for oral solution for the\ntreatment of rare and orphan gastrointestinal disorders with intestinal\nfailure, including microvillus inclusion disease and short bowel syndrome.\n\nFor more information about:\n\nJaguar Health, visit https://jaguar.health\n\nNapo Pharmaceuticals, visit napopharma.com (https://pr.report/scx4)\n\nNapo Therapeutics, visit napotherapeutics.com (https://pr.report/scx5)\n\nForward-Looking Statements\n\nCertain statements in this press release constitute \"forward-looking\nstatements.\" These include statements regarding payment of dividends,\nconversion of the Preferred Stock, Jaguar's expectation that its intestinal\nfailure program will continue to provide clinical proof-of-concept milestones,\nand Jaguar's expectation that the Company will file an NDA with the U.S. Food\nand Drug Administration for the MVID indication in mid-2027. In some cases,\nyou can identify forward-looking statements by terms such as \"may,\" \"will,\"\n\"should,\" \"expect,\" \"plan,\" \"aim,\" \"anticipate,\" \"could,\" \"intend,\" \"target,\"\n\"project,\" \"contemplate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential\" or\n\"continue\" or the negative of these terms or other similar expressions. The\nforward-looking statements in this release are only predictions. Jaguar has\nbased these forward-looking statements largely on its current expectations and\nprojections about future events. These forward-looking statements speak only\nas of the date of this release and are subject to several risks,\nuncertainties, and assumptions, some of which cannot be predicted or\nquantified and some of which are beyond Jaguar's control. Except as required\nby applicable law, Jaguar does not plan to publicly update or revise any\nforward-looking statements contained herein, whether as a result of any new\ninformation, future events, changed circumstances or otherwise.\n\nContact:\n\nhello@jaguar.health\n\nJaguar-JAGX\n\nSOURCE: Jaguar Health, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-provides-update-regarding-special-stock-dividend-1236812)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSFl8k4a-20261014","title":"Jaguar Health Provides Update Regarding Special Stock Dividend","author":"ACCESSWIRE","ticker":"JAGX","created":"2026-10-14T20:15:00.128Z","tickers":["JAGX"],"exchange":"NASDAQ","article_body":"SAN FRANCISCO, CA / ACCESS Newswire (https://www.accessnewswire.com/) /\nOctober 14, 2026 / Jaguar Health, Inc. (https://pr.report/scwz) (NASDAQ:JAGX\n(https://pr.report/scx0)) (\"Jaguar\" or \"the Company\") today provided an update\nin connection with the Company's previously announced (https://pr.report/scx1)\nspecial stock dividend (the \"Special Stock Dividend\"), which is payable on\nOctober 15, 2026, to holders of Jaguar common stock and certain outstanding\nwarrants as of record on October 13, 2026, to announce that The Nasdaq Stock\nMarket LLC (\"Nasdaq\") has indicated that the ex-dividend date for the Special\nStock Dividend is October 16, 2026 (the \"Ex-Dividend Date\"). The Special Stock\nDividend consists of the Company's Series R Convertible Preferred Stock (the\n\"Preferred Stock\").\n\nNasdaq has advised the Company that its shares of common stock will trade with\n\"due bills\" representing an assignment of the right to receive the dividend\nfrom the record date of October 13, 2026 until the Ex-Dividend Date (this\nperiod of time representing the \"Dividend Right Period\").\n\nStockholders who sell their shares of common stock during the Dividend Right\nPeriod will be selling their right to the Special Stock Dividend. Due bills\nobligate a seller of shares of common stock to deliver the Special Stock\nDividend payable on such shares of common stock to the buyer (the \"Dividend\nRight\"). The record date of October 13, 2026, will be used as the date for\nestablishing the due bill tracking of the Dividend Right to the holder of\nshares of common stock.\n\nDue bill obligations are customarily settled between the brokers representing\nthe buyers and the sellers of shares of common stock. The Company has no\nobligation for either the amount of the due bill or the processing of the due\nbill. Buyers and sellers of the Company's shares of common stock should\nconsult their brokers before trading to be sure they understand the effect of\nNasdaq's due bill procedures.\n\n\"Jaguar is issuing the Special Stock Dividend to reward and recognize our\npassionate and supportive stockholders and provide protection against\npotential dilution as we continue evaluation of strategic alternatives,\" said\nLisa Conte, Jaguar's founder, president, and CEO. \"We remain sharply focused\non our ongoing global development program for oral crofelemer as adjunctive\ntherapy to parenteral support for rare intestinal failure diseases, including\nmicrovillus inclusion disease (MVID) and short bowel syndrome with intestinal\nfailure (SBS-IF) for crofelemer powder for oral solution. Jaguar's intestinal\nfailure program is expected to continue to provide clinical milestones,\nincluding a planned New Drug Application (NDA) filing for crofelemer for MVID\nin mid-2027.\"\n\nFor additional information about the Special Stock Dividend and terms of the\nPreferred Stock and associated risk factors, please refer to the Form 8-K the\nCompany filed with the U.S. Securities and Exchange Commission on October 5,\n2026, which can be viewed on the Company's website by clicking here\n(https://pr.report/scx2).\n\nAbout Crofelemer\n\nCrofelemer is a novel, oral plant-based prescription medicine purified from\nthe red bark sap, also referred to as \"dragon's blood,\" of the Croton lechleri\ntree in the Amazon Rainforest. Napo Pharmaceuticals has established a\nsustainable harvesting program, under fair trade practices, for crofelemer to\nensure a high degree of quality, ecological integrity, and support for\nindigenous communities.\n\nAbout the Jaguar Health Family of Companies\n\nJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company\nfocused on developing novel proprietary prescription medicines sustainably\nderived from plants from rainforest areas for people and animals with\ngastrointestinal distress. Jaguar family companies Napo Pharmaceuticals, Inc.\n(Napo) and Napo Therapeutics S.p.A. focus on the development and\ncommercialization of novel crofelemer powder for oral solution for the\ntreatment of rare and orphan gastrointestinal disorders with intestinal\nfailure, including microvillus inclusion disease and short bowel syndrome.\n\nFor more information about:\n\nJaguar Health, visit https://jaguar.health\n\nNapo Pharmaceuticals, visit napopharma.com (https://pr.report/scx4)\n\nNapo Therapeutics, visit napotherapeutics.com (https://pr.report/scx5)\n\nForward-Looking Statements\n\nCertain statements in this press release constitute \"forward-looking\nstatements.\" These include statements regarding payment of dividends,\nconversion of the Preferred Stock, Jaguar's expectation that its intestinal\nfailure program will continue to provide clinical proof-of-concept milestones,\nand Jaguar's expectation that the Company will file an NDA with the U.S. Food\nand Drug Administration for the MVID indication in mid-2027. In some cases,\nyou can identify forward-looking statements by terms such as \"may,\" \"will,\"\n\"should,\" \"expect,\" \"plan,\" \"aim,\" \"anticipate,\" \"could,\" \"intend,\" \"target,\"\n\"project,\" \"contemplate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential\" or\n\"continue\" or the negative of these terms or other similar expressions. The\nforward-looking statements in this release are only predictions. Jaguar has\nbased these forward-looking statements largely on its current expectations and\nprojections about future events. These forward-looking statements speak only\nas of the date of this release and are subject to several risks,\nuncertainties, and assumptions, some of which cannot be predicted or\nquantified and some of which are beyond Jaguar's control. Except as required\nby applicable law, Jaguar does not plan to publicly update or revise any\nforward-looking statements contained herein, whether as a result of any new\ninformation, future events, changed circumstances or otherwise.\n\nContact:\n\nhello@jaguar.health\n\nJaguar-JAGX\n\nSOURCE: Jaguar Health, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-provides-update-regarding-special-stock-dividend-1236812)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-14T20:15:00.175742363Z","server_sent_at_ms":1792008900175},"received_at":"2026-10-14T20:15:00.296Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-provides-update-regarding-special-stock-dividend-1236812"},"analysis":{"id":"157732","press_release_id":"169485","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["special dividend of convertible preferred stock tied to protection against potential dilution -- review terms in the October 5 Form 8-K","company continues evaluation of strategic alternatives, signaling uncertainty"],"eventType":"dividend","narrative":"Jaguar Health announced that Nasdaq set the ex-dividend date of October 16, 2026 for its previously announced Special Stock Dividend of Series R Convertible Preferred Stock.\n\nShares will trade with due bills from the October 13 record date until the ex-dividend date, meaning sellers during that period give up their right to the dividend.\n\nCEO Lisa Conte framed the dividend as reward for stockholders and protection against potential dilution while the company evaluates strategic alternatives, with an NDA filing for crofelemer in MVID targeted for mid-2027.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Due-bill mechanics for JAGX special preferred dividend -- traders must hold through Oct 16 to capture the dividend right."},"keyFigures":{"drugName":"crofelemer","customDimensions":{"record_date":"October 13, 2026","ex_dividend_date":"October 16, 2026","nda_filing_target":"mid-2027 for crofelemer in MVID","dividend_instrument":"Series R Convertible Preferred Stock"}},"quotedText":"Jaguar is issuing the Special Stock Dividend to reward and recognize our passionate and supportive stockholders and provide protection against potential dilution as we continue evaluation of strategic alternatives","namedEntities":{"people":[{"name":"Lisa Conte","role":"founder, president, and CEO"}],"products":["Series R Convertible Preferred Stock","crofelemer powder for oral solution"],"companies":[{"name":"Jaguar Health, Inc.","ticker":"JAGX"},{"name":"The Nasdaq Stock Market LLC","relationship":"exchange"},{"name":"Napo Pharmaceuticals, Inc.","relationship":"subsidiary"},{"name":"Napo Therapeutics S.p.A.","relationship":"subsidiary"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Procedural update on an already-announced special stock dividend: Nasdaq set the ex-dividend date (Oct 16) with due-bill mechanics. No new financial terms or strategic-alternatives outcome disclosed."},"tickerRelevance":{"others":[],"primary":"JAGX"},"globalImportance":18,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"procedural dividend-date update","issuerAuthored":true,"retailFavoriteBoost":"small"}},"event_type":"dividend","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Jaguar Health announced that Nasdaq set the ex-dividend date of October 16, 2026 for its previously announced Special Stock Dividend of Series R Convertible Preferred Stock.\n\nShares will trade with due bills from the October 13 record date until the ex-dividend date, meaning sellers during that period give up their right to the dividend.\n\nCEO Lisa Conte framed the dividend as reward for stockholders and protection against potential dilution while the company evaluates strategic alternatives, with an NDA filing for crofelemer in MVID targeted for mid-2027.","key_figures":{"drugName":"crofelemer","customDimensions":{"record_date":"October 13, 2026","ex_dividend_date":"October 16, 2026","nda_filing_target":"mid-2027 for crofelemer in MVID","dividend_instrument":"Series R Convertible Preferred Stock"}},"named_entities":{"people":[{"name":"Lisa Conte","role":"founder, president, and CEO"}],"products":["Series R Convertible Preferred Stock","crofelemer powder for oral solution"],"companies":[{"name":"Jaguar Health, Inc.","ticker":"JAGX"},{"name":"The Nasdaq Stock Market LLC","relationship":"exchange"},{"name":"Napo Pharmaceuticals, Inc.","relationship":"subsidiary"},{"name":"Napo Therapeutics S.p.A.","relationship":"subsidiary"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T20:15:05.219Z","global_importance":18,"audience_relevance":25,"importance_components":{"tickerTier":"micro-cap","eventGravity":"procedural dividend-date update","issuerAuthored":true,"retailFavoriteBoost":"small"}},"durationMs":4801,"modelName":"glm-5.3-flashx"}}